Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kairos Pharma Ltd. (KAPA:NYSE), powered by AI.
Kairos Pharma Ltd. is currently trading at $0.30. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Kairos Pharma Ltd. on Alpha Lenz.
Kairos Pharma Ltd.'s P/E ratio is -1.0.
“Kairos Pharma Ltd. trades at a P/E of -1.0 (undervalued) with modest ROE of -98.0%.”
Ask for details →Kairos Pharma Ltd. is a pharmaceutical company focused on the research, development, and commercialization of innovative therapies. Its primary function is to advance treatments that target niche, unmet medical needs, particularly in the fields of oncology and degenerative diseases. The company is committed to harnessing cutting-edge scientific advancements and biotechnology, working alongside healthcare professionals and researchers to bring viable solutions to the market. Notable features include its robust pipeline of clinical trials that explore novel drug candidates and proprietary platforms aimed at improving patient outcomes. Kairos Pharma Ltd. plays a pivotal role in the healthcare sector, contributing to the development of new medications that offer hope to patients and healthcare providers alike. By addressing specialized medical demands, the company influences the pharmaceutical landscape and supports the ongoing evolution of targeted therapies.
“Kairos Pharma Ltd. trades at a P/E of -1.0 (undervalued) with modest ROE of -98.0%.”
Ask for details →Kairos Pharma Ltd. (ticker: KAPA) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 1 employees. Market cap is $6M.
The current price is $0.299 with a P/E ratio of -1.01x and P/B of 0.87x.
ROE is -97.99%.